Neurocrine Biosciences anticipates initiating a Phase 2 study with the selective M4 agonist HTL-0016878 in schizophrenia in 2022 and Phase 1 studies for a dual M1/M4 and selective M1 agonist in 2023 ...
Cocaine use can quickly escalate into cocaine use disorder, primarily driven by surges in dopamine from the ventral tegmental area to the nucleus accumbens (NAc). While dopamine-targeted treatments ...
FLAME analysis suggests COPD exacerbation risk spikes for 3 months after stopping LAMA or ICS, underscoring adherence and careful step-down.
In a previous article, I made the case that little has changed within the antipsychotic drug landscape over the past 70 years since the only effective medications for the treatment of schizophrenia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results